C

Centricity Research | Centricity Research Halifax

Research site

(Unclaimed)

Location

36 solutions drive suite 420, Halifax, Nova Scotia, Canada

Site insights

Top conditions

Top treatments

ALZ-801

Gantenerumab

BOTOX

Aducanumab

Psilocybin

ABBV-916

ALZ- 801

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 10 total trials

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting

Alzheimer's Disease (AD)

Drug: Placebo

Drug: ABBV-916

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest H...

Active, not recruiting

Huntington Disease

Drug: Tominersen 60 mg

Drug: Placebo

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Active, not recruiting

Early Alzheimer's Disease

Drug: Experimental: ALZ-801

Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

The goal of this clinical trial is to investigate treatment with psilocybin and psychotherapy for the treatment of people with Alcohol Use Disorder (...

Active, not recruiting

Alcohol Use Disorder

Drug: Psilocybin

Drug: Placebo